China Pharma HoldingCPHI -10.97%26 Current Ratio is 0.28 as of Mar. 2026, which is 64% below its 10-year median of 0.77. GuruFocus rates CPHI with a GF Score™ of 26/100 and a GF Value™ of $0.24 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 998 Drug Manufacturers companies, China Pharma Holding ranks worse than 95.89% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. China Pharma Holding's current ratio for the quarter that ended in Mar. 2026 was 0.28.
China Pharma Holding has a current ratio of 0.28. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If China Pharma Holding has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for China Pharma Holding's Current Ratio or its related term are showing as below:
CPHI'
s Current Ratio Range Over the Past 10 Years
Min: 0.28 Med: 0.77 Max: 1.69
Current: 0.28
During the past 13 years, China Pharma Holding's highest Current Ratio was 1.69. The lowest was 0.28. And the median was 0.77.
CPHI's Current Ratio is ranked worse than 95.89% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs CPHI: 0.28
China Pharma Holding (AMEX:CPHI) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
China Pharma Holding Current Ratio Related Terms
China Pharma Holding Current Ratio Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPHI vs TXMD, RMTI, AYTU: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Current Ratio distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (CPHI) has a Current Ratio of 0.28 as of Mar. 2026. This is 64% below median its historical median of 0.77. Over the past decade, China Pharma Holding's Current Ratio has ranged from 0.28 to 1.69. According to the industry distribution chart, China Pharma Holding ranks #957 out of 998 companies in the Drug Manufacturers industry, placing it in the top 95.9%.
Is China Pharma Holding's Current Ratio too high?
China Pharma Holding's current Current Ratio of 0.28 is 64% below median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 1.69. The Drug Manufacturers industry median Current Ratio is 2.00. China Pharma Holding's value of 0.28 is 86% below this industry median. Based on the distribution chart, China Pharma Holding ranks #957 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Pharma Holding has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Current Ratio compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #957 out of 998 companies for Current Ratio. This places China Pharma Holding in the lower half of its industry. The industry median Current Ratio is 2.00. China Pharma Holding's value of 0.28 is 86% below this benchmark. Historically, China Pharma Holding's own Current Ratio has ranged from 0.28 to 1.69 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 2.00, China Pharma Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Pharma Holding's current Current Ratio of 0.28 is 86% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current Current Ratio is 0.28, which is 64% below median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
Based on GuruFocus' analysis, China Pharma Holding (CPHI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.57 — trading 137.5% above its estimated fair value. The current Current Ratio is 0.28, which is 64% below median its 10-year median of 0.77 and 86% below the Drug Manufacturers industry median of 2.00. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For China Pharma Holding (CPHI), the current Current Ratio is 0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (CPHI) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of $0.57 is trading 137.5% above its estimated GF Value™ of $0.24.
GuruFocus considers China Pharma Holding to be Significantly Overvalued.
Key valuation signals for CPHI:
Current Ratio: 0.28 (64% below median its 10-year median of 0.77)
GF Value™: $0.24 vs. price of $0.57 (137.5% above fair value)
Industry Position: 86% below the Drug Manufacturers median (#957 of 998)
No single metric tells the full story. See the CPHI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for CPHI
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHI has been successfully added to your 
